Katrina Bawden
Family · Salt Lake City, UTNPI 1760863880
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $247,775 of the $394,516 with a category attached, or 62.8%. 44 manufacturers reported payments, led by Biogen at 37.8% of the total. Among family clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,612 payments — averaging $244.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$149K
- TG Therapeutics, Inc.$147K
- ANI Pharmaceuticals, Inc.$43K
- Amgen$11K
- Banner Life Sciences, LLC$10K
- Sanofi$10K
- plus $24K from 38 others
Across 1 payment — averaging $51,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$52K
What the payments were for
- Consulting fees$37,3749%
- Speaking & faculty fees$247,77563%
- Travel & lodging$81,48721%
- Food & beverage$27,6557%
- Education$2250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$394,516 in reported general payments places this provider in the 95th percentile of 1,460 family providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AubagioTeriflunomide | 16 | $155,363 |
| CopaxoneGlatiramer Acetate | 13 | $123,742 |
| TecfideraDimethyl Fumarate | 12 | $111,521 |
| Dalfampridine ErDalfampridine | 75 | $46,368 |
| Glatiramer Acetate | 17 | $26,983 |
| Nurtec OdtRimegepant Sulfate | 18 | $17,864 |
| Ajovy SyringeFremanezumab-Vfrm | 22 | $15,778 |
| Dimethyl Fumarate | 29 | $4,896 |
| Gabapentin | 154 | $4,139 |
| Baclofen | 176 | $4,114 |
| Carbamazepine ErCarbamazepine | 23 | $2,679 |
| Teriflunomide | 43 | $2,601 |
| Carbamazepine | 26 | $1,639 |
| CarbatrolCarbamazepine | 13 | $1,243 |
| Modafinil | 39 | $1,092 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiAubagio | $9,830 | $155,36316 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $57 | $123,74213 claims |
| BiogenTecfidera | $149,191 | $111,52112 claims |
| PfizerNurtec Odt | $182 | $17,86418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,460 family providers in Utah.
Other family in Salt Lake City
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Mary SteinbackSalt Lake City$189K
- Jennalyn MayeuxSalt Lake City$151K
- Kacie Doyle-DelgadoSalt Lake City$80K
- Melonie ThompsonSalt Lake City$45K
- Keisa LynchSalt Lake City$39K
- Christina CardonSalt Lake City$36K
- Jessica ArbogastSalt Lake City$20K
- Jennifer LloydSalt Lake City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.